Eli Lilly experienced positive price action fueled by sustained momentum following its robust second-quarter earnings report and an upward revision to its full-year financial outlook. Strong demand for key therapeutic franchises, particularly tirzepatide-based treatments Mounjaro for type 2 diabetes and Zepbound for weight management, continues to surpass market expectations. The company’s top-line revenue and bottom-line earnings significantly outpaced Wall Street estimates, reinforcing investor confidence in its capacity to expand manufacturing capacity and capture market share in the rapidly expanding metabolic and obesity drug sector. Upward earnings estimate revisions from analysts over recent weeks have further supported the…